24-WEEK OPEN LABEL EXTENSION TO A RANDOMIZED, 6-WEEK DOUBLE BLIND, PLACEBO CONTROLLED STUDY, TO EVALUATE THE SAFETY AND TOLERABILITY OF FLEXIBLE DOSES OF EXTENDED RELEASE OROS® PALIPERIDONE IN THE TREATMENT OF GERIATRIC SUBJECTS WITH SCHIZOPHRENIA: